Ultimovacs - Line of sight on INITIUM top-line readout
Ultimovacs has announced an amendment to the Phase II INITIUM trial, assessing lead cancer vaccine UV1 in combination with PD-1 checkpoint inhibitor nivolumab and CTLA-4 checkpoint inhibitor ipilimumab for the first-line treatment of malignant melanoma. The amendment allows the company to commence data analysis from mid-January 2024 and share top-line results in March or April 2024. This practical and proactive approach assists in unlocking the value of the programme (out-licensing) or progressing to pivotal studies if the data are positive. Top-line results were initially expected in H123, but the timeline was pushed back twice to H223 and H124 as patients were taking longer than expected to experience disease progression. We view this as a possible positive indicator for trial success (although not definitive as it is possible that the control arm may be experiencing slower than expected progression).Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.